Market capitalization | $34.68m |
Enterprise Value | $76.10m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.59 |
P/S ratio (TTM) P/S ratio | 0.27 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 1,404.02% |
Revenue (TTM) Revenue | $128.94m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
6 Analysts have issued a Atara Biotherapeutics Inc forecast:
6 Analysts have issued a Atara Biotherapeutics Inc forecast:
Dec '24 |
+/-
%
|
||
Revenue | 129 129 |
1,405%
1,405%
|
|
Gross Profit | 108 108 |
1,361%
1,361%
|
|
EBITDA | -74 -74 |
71%
71%
|
EBIT (Operating Income) EBIT | -78 -78 |
71%
71%
|
Net Profit | -85 -85 |
69%
69%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Anhco Nguyen |
Employees | 153 |
Founded | 2012 |
Website | www.atarabio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.